CN113940943A - 淫羊藿次苷ⅰ的用途 - Google Patents

淫羊藿次苷ⅰ的用途 Download PDF

Info

Publication number
CN113940943A
CN113940943A CN202111211629.7A CN202111211629A CN113940943A CN 113940943 A CN113940943 A CN 113940943A CN 202111211629 A CN202111211629 A CN 202111211629A CN 113940943 A CN113940943 A CN 113940943A
Authority
CN
China
Prior art keywords
icariside
epimedium extract
fermented
pichia pastoris
epimedium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111211629.7A
Other languages
English (en)
Chinese (zh)
Inventor
李慧灵
黄佳俊
陈川
张利民
罗冬章
林育成
周金林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Golden Health Biotechnology Co ltd
Original Assignee
Golden Health Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Golden Health Biotechnology Co ltd filed Critical Golden Health Biotechnology Co ltd
Priority to CN202111211629.7A priority Critical patent/CN113940943A/zh
Priority to PCT/CN2021/135559 priority patent/WO2023065478A1/fr
Publication of CN113940943A publication Critical patent/CN113940943A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A61K36/296—Epimedium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/102—Plasmid DNA for yeast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202111211629.7A 2021-10-18 2021-10-18 淫羊藿次苷ⅰ的用途 Pending CN113940943A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202111211629.7A CN113940943A (zh) 2021-10-18 2021-10-18 淫羊藿次苷ⅰ的用途
PCT/CN2021/135559 WO2023065478A1 (fr) 2021-10-18 2021-12-04 Utilisation d'icariside i

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111211629.7A CN113940943A (zh) 2021-10-18 2021-10-18 淫羊藿次苷ⅰ的用途

Publications (1)

Publication Number Publication Date
CN113940943A true CN113940943A (zh) 2022-01-18

Family

ID=79331333

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111211629.7A Pending CN113940943A (zh) 2021-10-18 2021-10-18 淫羊藿次苷ⅰ的用途

Country Status (2)

Country Link
CN (1) CN113940943A (fr)
WO (1) WO2023065478A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023065478A1 (fr) * 2021-10-18 2023-04-27 广东金骏康生物技术有限公司 Utilisation d'icariside i

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101513427A (zh) * 2009-01-22 2009-08-26 贵州同济堂制药有限公司 朝藿定c的用途
CN107890475A (zh) * 2017-12-05 2018-04-10 江苏康缘药业股份有限公司 淫羊藿提取物的制备方法与制得的提取物
CN109369748A (zh) * 2018-10-29 2019-02-22 广东金骏康生物技术有限公司 一种淫羊藿次苷ⅰ类化合物、衍生物、药物组合物及其应用
CN109369747A (zh) * 2018-10-29 2019-02-22 广东金骏康生物技术有限公司 淫羊藿次苷ⅰ化合物及其衍生物、药物组合物及其制备方法和应用
CN112138017A (zh) * 2020-08-27 2020-12-29 上海中医药大学 淫羊藿苷的酶解产物及其主要组分宝藿苷i的医药用途
CN113136378A (zh) * 2021-06-22 2021-07-20 广东金骏康生物技术有限公司 一种鼠李糖苷酶TpeRha突变体及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113940943A (zh) * 2021-10-18 2022-01-18 广东金骏康生物技术有限公司 淫羊藿次苷ⅰ的用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101513427A (zh) * 2009-01-22 2009-08-26 贵州同济堂制药有限公司 朝藿定c的用途
CN107890475A (zh) * 2017-12-05 2018-04-10 江苏康缘药业股份有限公司 淫羊藿提取物的制备方法与制得的提取物
CN109369748A (zh) * 2018-10-29 2019-02-22 广东金骏康生物技术有限公司 一种淫羊藿次苷ⅰ类化合物、衍生物、药物组合物及其应用
CN109369747A (zh) * 2018-10-29 2019-02-22 广东金骏康生物技术有限公司 淫羊藿次苷ⅰ化合物及其衍生物、药物组合物及其制备方法和应用
CN112138017A (zh) * 2020-08-27 2020-12-29 上海中医药大学 淫羊藿苷的酶解产物及其主要组分宝藿苷i的医药用途
CN113136378A (zh) * 2021-06-22 2021-07-20 广东金骏康生物技术有限公司 一种鼠李糖苷酶TpeRha突变体及其制备方法和应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FEIFEIXU等: "Anti-osteoporosis effect of Epimedium via an estrogen-like mechanism based on a system-level approach", 《JOURNAL OF ETHNOPHARMACOLOGY》 *
JINGCONG XIE等: "Biochemical characterization of a novel hyperthermophilic α-L-rhamnosidase from Thermotoga petrophila and its application in production of icaritin from epimedin C with a thermostable β-glucosidase", 《PROCESS BIOCHEMISTRY》 *
LUPING QIN等: "Antiosteoporotic chemical constituents from Er-Xian Decoction, a traditional Chinese herbal formula", 《JOURNAL OF ETHNOPHARMACOLOGY》 *
MINGMING LIU等: "Osteoblasts Proliferation and Differentiation Stimulating Activities of the Main Components of Epimedii folium", 《PHARMACOGN MAG.》 *
YUNBIN LYU等: "Efficient bioconversion of epimedin C to icariin by a glycosidase from Aspergillus nidulans", 《BIORESOUR TECHNOL.》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023065478A1 (fr) * 2021-10-18 2023-04-27 广东金骏康生物技术有限公司 Utilisation d'icariside i

Also Published As

Publication number Publication date
WO2023065478A1 (fr) 2023-04-27

Similar Documents

Publication Publication Date Title
CN101624570B (zh) 中药培养养殖肉灵芝方法及养殖肉灵芝保健品的制备方法
CN104232441A (zh) 一种健康保健养生虫草酒及其制备方法
CN113577128A (zh) 一种黄芪发酵液及其制备方法和应用
CN113940943A (zh) 淫羊藿次苷ⅰ的用途
CN104257696A (zh) 一种降糖稳糖酵母菌粉及其制备方法和应用
CN108576816A (zh) 一种增加骨密度的组合物
CN110720516A (zh) 骨营养特膳食品及其制备方法和应用
US20070014811A1 (en) Agents For Treating Osteoporosis And Inhibiting Osteoclast Formation
CN116211956B (zh) 一种调节肠道和/或改善肥胖的组合物和制备方法、一种咀嚼片及其应用
CN104800298B (zh) 一种用于治疗痛风的中药颗粒制剂及其制备方法
RU2391996C1 (ru) Средство для лечения сердечно-сосудистых заболеваний
CN112472733B (zh) 一种促进钙口服吸收的葛花提取物
CN108771070B (zh) 冠突散囊菌发酵芹菜汁的复合功能饮品及制备方法和用途
CN106389477A (zh) 一种土生戈登氏菌的全细胞植物油提取物的制备方法和应用
CN112079938A (zh) 一种青稞多糖的提取方法、青稞多糖提取物及其应用
CN1240709C (zh) 人参果三醇组皂苷提取物及其提取、精制方法及其医药用途
CN106344599B (zh) 三萜皂苷类化合物的应用
CN111345419A (zh) 一种复合发酵型鲨鱼软骨粉保健饮品
KR20070090005A (ko) 스크라레올 또는 그 유도체를 포함하는 조성물 및 이의용도
CN1350860A (zh) 糖尿病人用的保健口服液生产工艺
CN115645466A (zh) 一种抗疲劳的中药有效部位组合物及其制备方法与应用
CN1548423A (zh) 双苄基异喹啉-(7-0-11')-单醚键生物碱衍生物及类似物在治疗纤维化有关疾病中的用途
JPH10236967A (ja) 甘草発酵物からなる薬剤
CN116617258A (zh) 一种治疗溃疡性结肠炎药菌组合物的制备方法及应用
CN1314414C (zh) 一种治疗和预防骨质疏松症的中药及其制备工艺

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20220118

RJ01 Rejection of invention patent application after publication